Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9150335 | 0.85 | RARB (0.44) | GPR84MEN1KMT2ACNR2 | |
| SCHEMBL7211324 | 0.75 | ALDH1A1 (0.51) | GPR84CNR2 | |
| SCHEMBL2141794 | 0.74 | GPR84 (0.39) | TLR8GPR84ICMTKMT2ACNR2 | |
| SCHEMBL24159217 | 0.71 | ALDH1A1 (0.36) | TLR8OPRM1CNR1ICMTKMT2A | |
| SCHEMBL27723852 | 0.70 | BRD4 (0.37) | TLR8MAPK1KMT2A | |
| SCHEMBL27774707 | 0.69 | TLR8 (0.52) | TLR8CNR1NPC1ICMTMEN1 | |
| SCHEMBL3225639 | 0.69 | TLR8 (0.46) | TLR8CNR1ICMTMEN1KMT2A | |
| SCHEMBL3219891 | 0.69 | CNR1 (0.48) | GPR84CNR1CNR2 | |
| SCHEMBL9019256 | 0.67 | RARB (0.45) | GPR84MEN1KMT2A | |
| SCHEMBL251002 | 0.67 | CNR2 (0.44) | TLR8GPR84CNR1ICMTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986856-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST | Opiant Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3890724-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST | Opiant Pharmaceuticals, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020257336-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST | OPIANT PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020118048-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST | OPIANT PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3634479-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | President and Fellows of Harvard College (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3475299-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | President and Fellows of Harvard College (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018227200-A1 | METHOD TO IDENTIFY COMPOUNDS USEFUL TO TREAT DYSREGULATED LIPOGENESIS, DIABETES, AND RELATED DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018005551-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-01-04 | — | — | WO | disclosed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | TLR8 957/4885OPRM1 32/4885OPRD1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.